Access To Medicine Foundation

Often searched

Index ranking

Vacancies

10 year analysis

  • Healthcare inequity
    • How big is the problem?
    • How we drive change
    • Our story
    • Our impact
    • How big is the problem?
    • How we drive change
    • Our story
    • Our impact
  • Become a catalyst
    • Investors
    • Companies
    • Government & policymakers
    • Events & engagements
    • Investors
    • Companies
    • Government & policymakers
    • Events & engagements
  • Sectors and research
    • R&D-based pharma companies
    • Medical gas companies
    • Generic medicine manufacturers
    • Diagnostics companies
    • Vaccine manufacturers
    • Resource centre
    • Company profiles & report cards
    • R&D-based pharma companies
    • Medical gas companies
    • Generic medicine manufacturers
    • Diagnostics companies
    • Vaccine manufacturers
    • Resource centre
    • Company profiles & report cards
  • Cross-Sector Programmes
    • Antimicrobial resistance
    • Diabetes care
    • Antimicrobial resistance
    • Diabetes care
  • On the pulse of global health
    • Access insights
    • The Health Equity podcast
    • Access insights
    • The Health Equity podcast
  • News
  • Our team
  • Featured insights
  • Governance & financials
  • Vacancies
  • Media coverage
  • FAQ
  • Contact us

Research Archives

Welcome to the Research Archives, where you can access best practices and key findings from our earlier reports. As new reports are published, older insights are archived here to ensure continued access to valuable information. Explore these past resources for reference, reflection and continued learning.

2022 Access to Medicine Index

Findings

  • Key finding 1: R&D priorities - Some companies engaging in R&D for emerging infectious diseases, but pipeline mainly empty

  • Key finding 2: Licencing - First voluntary licence for a cancer treatment is a promising sign for future expansion of access to innovative medicines

  • Key finding 3: Access planning & strategies - More access plans and strategies to expand access to more products, but with limited breadth and depth

  • Industry trends - 2022 Index finds companies approach access to medicine more systematically, yet show stagnation in some key areas

  • Special report on progress analysis finding - Companies make progress in access planning, but little change in makeup of R&D pipelines

  • Special report on progress analysis finding - Progress seen at board level as companies increasingly integrate strategies to address access to medicine

  • Special report on progress analysis finding - Industry makes progress on access strategies and voluntary licensing for products, but overall picture mixed

  • Special report on SRHR finding - How companies perform on ensuring access to their SRHR-related products for women and girls in LMICs

  • Special report on SRHR finding - For some SRHR-related diseases, R&D priorities are not being addressed

Best practices

  • Adapting business models to tackle access barriers and increase product reach

  • Accompanying licensing agreements with technology transfers to manufacturers

  • Making access plans for all late-stage R&D projects

  • Implementing a systematic access planning policy for R&D projects

  • Addressing heat stability of insulin products to allow for easier storage

  • Expanding access to diabetes care for children and young people in LMICs

  • Support for genomic database initiative could lead to better treatments across Africa

  • Approvals for new products to treat neglected tropical diseases and infectious diseases

  • Supporting researchers in LMICs to build capacity for R&D and clinical trials

  • Publishing comprehensive and transparent patent information

  • Promoting and rewarding the effective delivery of access initiatives at top levels

  • Scaling up inclusive business models to expand access to medicines for non-communicable diseases

  • Implementing strong access strategies across different country income classifications

  • Using partnerships to measure impact and outcomes of access programmes

  • Sharing IP assets to facilitate R&D targeting neglected tropical diseases

  • Creating an online cervical cancer programme to avoid disruptions to care during COVID-19

  • Setting a precedent with non-exclusive voluntary licence for a cancer compound

  • Tailoring pricing strategies according to the ability of countries and individuals to pay

  • A holistic approach to expanding access to contraceptive products

2022 Access to Medicine Index

Index finds more pharma companies moving to address access to medicine. Will they now go further?

Read more

Claudia Martínez

Director of Research

cmartinez@accesstomedicinefoundation.org

Get in touch

Access to Medicine Foundation

Interested in our work?

Access to Medicine Foundation is funded by

Terms & conditions

Privacy & cookie policy

Disclaimer

Copyright 2004 - 2025 Access to Medicine Foundation - All Rights Reserved